NorthSea Therapeutics: First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. Lead candidate Icosabutate for NASH in Ph 2b (first patient dosed Q3’19, interim analysis H2’20); clinical data shows improvement in NASH associated co-morbidity risk factors and liver enzymes. Pipeline includes Phase 1 ready dyslipidemia and late-stage preclinical Parenteral Nutrition Associated Liver Disease (PNALD) programs. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments - funds completion of Ph 2b ICONA study in NASH and advances two additional SEFA programs into the clinic in 2020-21.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Metabolic Disorders
Finance
Pre-earnings
Industry
Biotechnology
Investment Participation
CrossOvers
Listing
Private
Therapeutic Modalities
Small Molecule
Website:
Address:
Gooimeer 2 35
Naarden, 1411 DC
Netherlands

Company Participants at Solebury Trout Virtual Global Healthcare Conference Series

  • Rob de Ree, Chief Executive Officer & Board Member

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Summer 2020 NYC Private Company Showcase

New York, NY, August 10, 2020